Volume 13, Issue 2 (2-2015)                   IJRM 2015, 13(2): 93-100 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghaneei A, Jowkar A, Hasani Ghavam M R, Ghaneei M E. Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia. IJRM. 2015; 13 (2) :93-100
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-625-en.html
1- Department of Endocrinology, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Department of Endocrinology, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , akjowkar@gmail.com
3- Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4- Khatam-Ol- Anbia Clinic, Yazd, Iran
Abstract:   (9918 Views)
Background: 30% of patients with polycystic ovary syndrome (PCOS) show mild, transient hyperprolactinemia. It is suggested that a reduction of the dopamine inhibitory effect might raise both prolactin and luteinizing hormone.
Objective: To investigate the adjuvant cabergoline therapy effects on menstrual irregularity and androgen system in PCOS women with hyperprolactinemia.
Materials and Methods: This randomized clinical trial was done on 110 polycysticovary syndrome women with increased serum prolactin concentration [1.5 fold morethan normal level (>37.5 ng/ml)]. Participants were divided into two groups: Casegroup (n=55) treated with metformin 1gr/day and cabergoline 0.5 mg/week for 4months and control group (n=55) treated with metformin 1g/day and placeboweekly. Testosterone, prolactin, and dehydroepiandrosterone sulfate level weremeasured before and four months after intervention in two groups. Also, situation ofmenstrual cycles asked and recorded before and after intervention.
Results: We found decrease in the mean of dehydroepiandrosterone sulfate, weightand total testosterone level in the two groups after intervention but their changeswere not significant. Patients in case group showed a significant decrease in serumprolactin level before and after intervention (p<0.001), but no difference was foundin control group. All patients in both studied groups had irregular menstrual cycles,which regulate after intervention and the difference was significant (p=0.02).
Conclusion: The results showed that cabergoline can be used as a safe administration in PCOS patients with hyperprolactinemia to improve the menstrual cycles. Considering that the administration of cabergoline plus metformin may reduce the required duration and dose of metformin, patient acceptability of this approach is higher.
Full-Text [PDF 167 kb]   (301 Downloads) |   |   Full-Text (HTML)  (141 Views)  
Type of Study: Original Article |

References
1. Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Human Reprod Update 2006; 12: 673-683. [DOI:10.1093/humupd/dml036]
2. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191. [DOI:10.1016/S0002-9378(15)30642-6]
3. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008; 14: 367-378. [DOI:10.1093/humupd/dmn015]
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the outheastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
5. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69: 634-641. [DOI:10.1111/j.1365-2265.2008.03247.x]
6. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438. [DOI:10.1210/jc.85.7.2434]
7. Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online 2004; 8: 644-648. [DOI:10.1016/S1472-6483(10)61644-6]
8. Wood JR, Dumesic DA, Abbott DH, Strauss JF. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 2007; 92: 705-713. [DOI:10.1210/jc.2006-2123]
9. Toulis KA, Gouli DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009; 15: 297-307. [DOI:10.1093/humupd/dmp006]
10. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009; 15: 477-488. [DOI:10.1093/humupd/dmp008]
11. Rotterdam ESHRE/ ASRM- Sponsored PCOS consensus workshop group Hum Reprod. Review Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
12. Sengoku K, Tamate K, Takuma N, Yoshida T, Goishi K, Ishikawa M. The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. Hum Reprod 1997; 12: 474-477. [DOI:10.1093/humrep/12.3.474]
13. Boomsma CM, Fauser BCJM, Macklon NS. Pregnancy complications in women with olyscystic ovary syndrome. Semin Reprod Med 2008; 26: 72-84. [DOI:10.1055/s-2007-992927]
14. Duignam NM. Polycystic ovarian disease. Br J Obstet Gynaecol 1976; 83: 593. [DOI:10.1111/j.1471-0528.1976.tb00895.x]
15. Falaschi P, Frajese G, Rocco A, Toscano V, Sciarra F. Polycystic ovary syndrome and hyperprolactinemia. J Steroid Biochem 1977; 8: 13. [DOI:10.1016/0022-4731(77)90151-0]
16. Coremblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity. Fertil Steril 1982; 38: 549-552.
17. Işik AZ, Gülekli B, Zorlu CG, Ergin T, Gökmen O. Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol Obstet Invest 1997; 43: 183-185. [DOI:10.1159/000291850]
18. Doldi N, Papaleo E, De Santis L, Ferrari A. Hyperprolactinemia in IVF cycles: treatment vs no treatment and outcome of ovarian stimulation, oocyte retrieval and oocyte quality. Gynecol Endocrinol 2000; 14: 437-441. [DOI:10.3109/09513590009167716]
19. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine. 18th Ed. USA, Elsevier; 2011.
20. Webster J. Dopamine agonist in hyperprolactinemia. J Reprod Med 1999; 44: 1105-1110.
21. Falaschi P, Rocco, A, Del Pozo E. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 62: 348-351. [DOI:10.1210/jcem-62-2-348]
22. Prelevic GM, Wurzburger MI, Peric LJA. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary sydrome. J Endocrinol Invest 1987; 10: 389-395. [DOI:10.1007/BF03348155]
23. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812-819. [DOI:10.1210/jc.2002-020815]
24. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 85-87. [DOI:10.1016/S0889-8545(05)70187-X]
25. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, et al. A 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265-273. [DOI:10.1111/j.1365-2265.2006.02562.x]
26. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF . A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-909. [DOI:10.1056/NEJM199410063311403]
27. Pascal-Vigneron V, Weryha G, Bosc M, and Leclere J. Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse medicale (Paris, France, 1983) 1995; 24: 753-757.
28. Ajossa S, Paoletti AM, Guerriero S, Floris S, Mannias M, Melis GB. Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 1999; 71: 314-318. [DOI:10.1016/S0015-0282(98)00462-2]
29. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001; 16: 2263-2266. [DOI:10.1093/humrep/16.11.2263]
30. Paoletti AM, Cagnacci A, Depau GF, Orrù M, Ajossa S, Melis GB. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 1996; 66: 527-532. [DOI:10.1016/S0015-0282(16)58563-X]
31. Gómez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermann RC, et al. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab 2011; 96: 2484-2492. [DOI:10.1210/jc.2011-0075]
32. Prelevic GM, Wurzburger MI, Peric LJA. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary sydrome. J Endocrinol Invest 1987; 10: 389-395. [DOI:10.1007/BF03348155]
33. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 2004; 49: 361-367.
34. Kedikova S, Sirakov M, Boyadzhieva M. [Metformin efficiency for the adolescent PCOS treatment]. Akush Ginekol (Sofiia). 2012; 51: 6-10. (In Bulgarian)
35. Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, et al. Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy. Indian J Clin Biochem 2010; 25: 367-70. [DOI:10.1007/s12291-010-0090-2]
36. Velija-Ašimi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn J Basic Med Sci 2013; 13: 180-5. [DOI:10.17305/bjbms.2013.2359]
37. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17: 51-56. [DOI:10.1080/gye.17.1.51.56]
38. Chapman AJ, Wilson MD, Obhrai M, Sawers RS, Lynch SS, Royston JP, et al. Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1987; 27: 571-580. [DOI:10.1111/j.1365-2265.1987.tb01187.x]
39. Shlomo M, Kenneth SP, Reed L, Henry MK. Williams textbook of Endocrinilogy. 12th Ed. USA, Sunders/Elsevier; 2011.
40. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011; 96: 3493-3501. [DOI:10.1210/jc.2011-0501]
41. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94: 4938-4945. [DOI:10.1210/jc.2009-1674]
42. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecol Endocrinol 2010; 26: 173-178. [DOI:10.3109/09513590903215581]
43. Kenneth A, Steingold, Rogerio A, Lobo, Howard L, Judd, John KH, LU R, Jeffrey C. The Effect of Bromocriptine on Gonadotropin and Steroid Secretion in Polycystic Ovarian Disease. J Clin Endocrinol Metab 1986; 62: 1048-1051. [DOI:10.1210/jcem-62-5-1048]
44. The Rotterdam ESHRE/ASRM-Sposored pcos consensus workshop group 2004 revised 2003consensuson diagnostic criteria and long term health risks related to polycystic ovary syndrome (pcos). Hum Repord 2004; 19: 41-47.

Send email to the article author


© 2021 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb